Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Qualcomm, Novartis To Invest In Mobile Health, Aggregate Trial Data

This article was originally published in The Gray Sheet

Executive Summary

The companies say they are partnering to invest in start-ups that have potential to change healthcare delivery and are using Qualcomm’s 2net Platform in a clinical trial to aggregate patient data and personalize treatments.

You may also be interested in...



Big Tech Firms Target Health Care Space With Cheap Sensors In Smartphones

Recent activities by three smartphone giants point to a potential future where the phone itself more frequently serves as a monitoring or diagnosing device, in place of external sensors. If the trend rolls on, it could have important implications for the mobile health sector.

Digital Health Briefs: Post-Surgery Remote Monitoring; NHS England Technology Funding; Qualcomm Product

Study finds remote monitoring can assess patient mobility and correlates with length of stay. NHS England boosts technology fund by 250 million pounds. Qualcomm introduces 2net Mobile. More digital news.

Amneal Eyes Avastin And Praises $120m Biosimilar Development Savings

Amneal is close to a filed pipeline of three biosimilar products in the US, while furthering ambitions in the complex generics and 505(b)(2) space, management told the virtual J.P. Morgan Healthcare Conference.

Topics

Related Companies

UsernamePublicRestriction

Register

OM017175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel